The mitogen-activated protein kinases (MAPKs) are generally expressed in all cell types, yet they function to regulate specific responses that differ from cell type to cell type. The MAPKs most intensely studied are extracellular signal-regulated kinase (ERK)1/2, the p38 kinase (p38a, b, g and d), c-Jun N-terminal kinase (JNK)1, 2, 3 and ERK5. There is less known about ERK7 function and regulation. To demonstrate the interest in MAPKs, one needs to simply search PubMed for numbers of publications citing the different MAPKs. As of December 22, 2006 PubMed listed 33 261 papers that cited ERK1/2 (12 314), JNK (8727), p38 (12 005), ERK5 (202) and ERK7 (13). The reason for such intense study of MAPKs is their involvement in the cellular response to almost all stimuli, that activate membrane, cytoplasmic and/or nuclear signaling networks.
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How are MAPKs activated by such a plethora of stimuli but yet have highly specific biological functions? The answer is in part related to the spatio-temporal regulation of MAPKs within cells. As part of a threekinase module, MAPKs are phosphorylated and activated by MAPK kinases (MKKs). MAPK kinase kinases (MKKKs) phosphorylate and activate MKKs. Whereas there are at least eleven MAPKs, there are only seven MKKs, but at least 20 MKKKs. The differing regulatory domains and motifs encoded in the different MKKKs selectively control localization, activation and inactivation of associated MKKs and MAPKs. In addition, many MKKKs can phosphorylate and activate more than one class of MKKs providing for the ability to coordinately activate two or more different classes MAPKs in response to the activation of a specific MKKK. For example, the MKKK, MEKK3, can activate both p38 and ERK5. In addition, scaffold proteins such as kinase suppressor of Ras, b-arrestin and the JNK-interacting proteins organize MAPK modules in complexes with other proteins, control trafficking and subcellular location, and duration of MAPK signaling. Thus, the combination of differential control of MKKK activation and the organization of signaling complexes by scaffolding proteins provides a combinatorial diversity for the integration of MAPK networks in the cellular response to stimuli such as cytokines, growth factors, antigens, toxins, pharmacological drugs and stresses such as temperature change and irradiation, and changes in cell shape, cellcell interaction and extracellular matrix composition (Figure 1 ).
Given the role of MAPKs in so many critical responses required for cellular homeostasis, it is no wonder that loss of fine control of MAPK regulation resulting from mutation or changes in expression of proteins regulating MAPK signaling, such as activating Ras or Raf mutations, epidermal growth factor receptor overexpression or inactivation of MKK4, contribute to cancer. Changes in MAPK regulation appears to also contribute to inflammation and neurodegeneration and many other diseases. For these reasons, the MAPKs have been a focus of intense drug discovery programs by both academic laboratories and the biotechnology/pharmaceutical industry. To date, there have been at least 25 small molecule inhibitors targeting specific MAPKs, MKKs or MKKKs that have reached early-to late-stage clinical trials. Certainly for cancer, small molecule inhibitors targeting Raf or MKK1/2 are progressing in trials for many different tumor types.
To truly understand the nature of human diseases such as cancer, it is imperative to define the behavior of signaling networks in the cell and how the dynamics of signaling controls phenotype. A necessary goal for the future is to understand the dynamic spatio-temporal control of MAPK signaling networks and how they contribute to physiological responses in cells, organs and organisms. This requires a detailed understanding of how MAPK signaling networks are integrated with upstream inputs and parallel signaling pathways for the control of physiological responses, and how this integration of signaling networks is dysregulated in disease. To define network control by MAPKs, it is imperative to study the regulation and function of all MAPKs and how each contributes to the integration and spatio-temporal control of physiological responses. Success in defining the critical elements of a signaling network involves large-scale measurements of a biological system and to use these measurements in computational models to predict network behavior and biological outcome. Multiple approaches using RNA interference, targeted gene knockouts and knock-ins, chemical inhibitors and the use of combinatorial mixtures of stimulators and inhibitors of specific signaling pathways will be required to interrogate the behavior of the MAPK network and functional outputs in terms of cell responses both in vitro and in vivo. Such data will eventually be used to define a set of metrics to computationally model the dynamics of the MAPK network and how each MAPK contributes to specific physiological responses. Such cumulative analysis will be used to develop models to define 'MAPK signatures' that can be genetically and pharmacologically tested for use in discovery of novel therapeutic interventions, and potentially prognosis and optimizing treatment options.
In this special issue of Oncogene, we bring together 15 reviews that provide a broad overview of the function, regulation and integration of MAPK signaling networks. The reviews cumulatively demonstrate our depth of understanding of MAPK function and regulation but also point out our considerable deficiencies in understanding the complex integration of MAPKs in the network of signaling pathways within cells. We certainly are not close to a comprehensive systems map of MAPK function but as detailed in the 15 reviews this goal is well underway and achievable in the next 5-10 years. The review issue starts with a focus on regulation of MAPK signaling modules and transitions to the role of MAPKs in the control of cell cycle, the cancer phenotype and drug discovery targeting the MAPK pathways and upstream regulators. 
